Acute Graft Versus Host Disease Clinical Trial
Official title:
Pilot Study Evaluating Changes in Physical Function Measures in Stem Cell Transplant Patients at Risk for Steroid Myopathy
This trial investigates the changes in physical and functional tests over time in patients with suspected acute graft versus host disease (from a hematologic stem cell transplant) who started treatment with corticosteroids. Sometimes the transplanted cells from a donor can attack the body's normal cells (called graft-versus-host disease). Steroids are used to treat suspected graft-versus-host disease. Steroid myopathy (muscle weakness and fatigue) is a significant side effect of high dose steroid therapy, and can impair activities of daily of life. The goal of this trial is to learn how patients' physical activities and functions change over time while on GVHD-steroid treatment.
PRIMARY OBJECTIVE: I. To perform a pilot study to estimate the change in six physical and functional tests over time in patients with suspected acute graft-versus-host disease (GVHD) who have been initiated on treatment with corticosteroids. SECONDARY OBJECTIVES: I. To describe and potentially define steroid myopathy by following the patterns of the muscle loss and functional impairment in this population of patients. II. To follow steroid myopathy and describe its incidence, its severity, and the impact on non-relapse mortality in a homogeneous population of patients with suspected acute graft-versus-host disease (GVHD) who have been initiated on treatment with corticosteroids at a quaternary institution in the inpatient and outpatient setting. III. To estimate the adherence to an intermittently supervised exercise program in hematopoietic stem cell transplantation (HSCT) patients who are at risk of developing steroid myopathy. OUTLINE: Patients complete a physical function test over 15 minutes at baseline, and at days 14, 28, and 56. Patients also participate in an 8-week home-based strengthening and walking program consisting of a strengthening/resistance program for 30 minutes, 3 times a week, and walking program for 20-30 minutes at least 3 times a week. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01140984 -
Intra Arterial (IA) Steroids Infusion for Hepatic Acute Hepatic Graft Versus Host Disease (aGVHD)
|
N/A | |
Completed |
NCT00803010 -
Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation
|
Phase 2 | |
Withdrawn |
NCT04280471 -
Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease
|
Phase 1 | |
Withdrawn |
NCT02425813 -
Methylprednisolone Sodium Succinate in Treating Patients With Acute Graft-versus-Host Disease of the Gastrointestinal Tract
|
Phase 2 | |
Terminated |
NCT00038792 -
Phase I/II Trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD
|
Phase 1/Phase 2 | |
Terminated |
NCT02436460 -
A Study of AbGn-168H in Patients With Steroid Refractory Acute Graft-vs-Host Disease After Donor Stem Cell Transplant
|
Phase 1 | |
Not yet recruiting |
NCT01596192 -
PETCT for Diagnosing and Monitoring Acute GVHD
|
N/A | |
Completed |
NCT00726375 -
The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease
|
Phase 3 | |
Recruiting |
NCT05823675 -
Safety and Clinical Activity of Itolizumab in aGVHD
|
Phase 1 | |
Not yet recruiting |
NCT06386445 -
Study on the Serum Metabolic Markers and Early Complications After Allo-HSCT: Cohort Study
|
||
Recruiting |
NCT05443425 -
Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies
|
Phase 1 | |
Recruiting |
NCT03158896 -
Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease
|
Phase 1 | |
Not yet recruiting |
NCT06444022 -
hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation
|
Early Phase 1 | |
Active, not recruiting |
NCT04976699 -
CD24Fc for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)
|
Phase 3 | |
Terminated |
NCT04095858 -
Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)
|
Phase 3 | |
Terminated |
NCT00032773 -
Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD
|
Phase 1/Phase 2 | |
Completed |
NCT02359929 -
BMT Autologous MSCs for GvHD
|
Phase 1 | |
Withdrawn |
NCT00640497 -
Anti-CD3 & Anti-CD7 Ricin A Immunotoxin-Combination for Acute Graft Versus Host Disease
|
Phase 1/Phase 2 | |
Completed |
NCT03491215 -
Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02687646 -
Clinical Trial With MSC for Graft Versus Host Disease Treatment
|
Phase 1/Phase 2 |